These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 22108625)

  • 21. Can botulinum toxin type A injection technique influence the clinical outcome of patients with post-stroke upper limb spasticity? A randomized controlled trial comparing manual needle placement and ultrasound-guided injection techniques.
    Santamato A; Micello MF; Panza F; Fortunato F; Baricich A; Cisari C; Pilotto A; Logroscino G; Fiore P; Ranieri M
    J Neurol Sci; 2014 Dec; 347(1-2):39-43. PubMed ID: 25263601
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pectoral muscle spasms after mastectomy successfully treated with botulinum toxin injections.
    O'Donnell CJ
    PM R; 2011 Aug; 3(8):781-2. PubMed ID: 21871424
    [No Abstract]   [Full Text] [Related]  

  • 23. Evaluation of specific immune responses to BoNT/A and tetanus toxoid in patients undergoing treatment for neurologic disorders.
    Vlata Z; Tsatsakis A; Tzagournissakis M; Krambovitis E
    Endocr Metab Immune Disord Drug Targets; 2012 Sep; 12(3):268-73. PubMed ID: 22385115
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Determinants of botulinum toxin discontinuation in multiple sclerosis: a retrospective study.
    Latino P; Castelli L; Prosperini L; Marchetti MR; Pozzilli C; Giovannelli M
    Neurol Sci; 2017 Oct; 38(10):1841-1848. PubMed ID: 28766025
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neutralizing antibodies in dystonic patients who still respond well to botulinum toxin type A.
    Kranz G; Sycha T; Voller B; Kranz GS; Schnider P; Auff E
    Neurology; 2008 Jan; 70(2):133-6. PubMed ID: 18180443
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IncobotulinumtoxinA: A Highly Purified and Precisely Manufactured Botulinum Neurotoxin Type A.
    Kerscher M; Wanitphakdeedecha R; Trindade de Almeida A; Maas C; Frevert J
    J Drugs Dermatol; 2019 Jan; 18(1):52-57. PubMed ID: 30681794
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Satisfaction with botulinum toxin treatment in post-stroke spasticity: results from two cross-sectional surveys (patients and physicians).
    Bensmail D; Hanschmann A; Wissel J
    J Med Econ; 2014 Sep; 17(9):618-25. PubMed ID: 24841450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cortical activation changes in patients suffering from post-stroke arm spasticity and treated with botulinum toxin a.
    Tomášová Z; Hluštík P; Král M; Otruba P; Herzig R; Krobot A; Kaňovský P
    J Neuroimaging; 2013 Jul; 23(3):337-44. PubMed ID: 22212022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potentiation of botulinum toxin type A with oral anti-spasticity medications in the management of focal spasticity.
    Dai A
    J Rehabil Med; 2007 Mar; 39(2):189; author reply 189. PubMed ID: 17351705
    [No Abstract]   [Full Text] [Related]  

  • 30. Longitudinal assessment of the dose consistency of botulinum toxin type A (BOTOX) for cervical dystonia.
    Brashear A; Hogan P; Wooten-Watts M; Marchetti A; Magar R; Martin J
    Adv Ther; 2005; 22(1):49-55. PubMed ID: 15943222
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravesical botulinum toxin a injections do not benefit patients with ulcer type interstitial cystitis.
    Lee CL; Kuo HC
    Pain Physician; 2013; 16(2):109-16. PubMed ID: 23511677
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of switching therapy from complexing protein-containing botulinum toxin type A to a formulation with low immunogenicity in spasticity after stroke: a case report.
    Santamato A; Ranieri M; Panza F; Frisardi V; Micello MF; Filoni S; Fiore P
    J Rehabil Med; 2012 Sep; 44(9):795-7. PubMed ID: 22915045
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Botulinum neurotoxin neutralizing activity of immune globulin (IG) purified from clinical volunteers vaccinated with recombinant botulinum vaccine (rBV A/B).
    Shearer JD; Vassar ML; Swiderski W; Metcalfe K; Niemuth N; Henderson I
    Vaccine; 2010 Oct; 28(45):7313-8. PubMed ID: 20816903
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors influencing secondary non-response to botulinum toxin type A injections in cervical dystonia.
    Ferreira JJ; Colosimo C; Bhidayasiri R; Marti MJ; Maisonobe P; Om S
    Parkinsonism Relat Disord; 2015 Feb; 21(2):111-5. PubMed ID: 25499753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cortical activity modulation by botulinum toxin type A in patients with post-stroke arm spasticity: real and imagined hand movement.
    Veverka T; Hluštík P; Hok P; Otruba P; Tüdös Z; Zapletalová J; Krobot A; Kaňovský P
    J Neurol Sci; 2014 Nov; 346(1-2):276-83. PubMed ID: 25255982
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure.
    Dressler D; Bigalke H; Benecke R
    J Neurol; 2003 Aug; 250(8):967-9. PubMed ID: 12928917
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy.
    Albrecht P; Jansen A; Lee JI; Moll M; Ringelstein M; Rosenthal D; Bigalke H; Aktas O; Hartung HP; Hefter H
    Neurology; 2019 Jan; 92(1):e48-e54. PubMed ID: 30464031
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The broadening application of chemodenervation in X-linked dystonia-parkinsonism (Part II): an open-label experience with botulinum toxin-A (Dysport®) injections for oromandibular, lingual, and truncal-axial dystonias.
    Rosales RL; Ng AR; Santos MM; Fernandez HH
    Int J Neurosci; 2011; 121 Suppl 1():44-56. PubMed ID: 21348790
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and self-reported efficacy of botulinum toxin for adult spasticity in current clinical practice: a prospective observational study.
    Muller F; Cugy E; Ducerf C; Delleci C; Guehl D; Joseph PA; Burbaud P; Dehail P
    Clin Rehabil; 2012 Feb; 26(2):174-9. PubMed ID: 21937525
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment of focal dystonia with botulinum toxin A].
    Sojer M; Wissel J; Müller J; Poewe W
    Wien Klin Wochenschr; 2001; 113 Suppl 4():6-10. PubMed ID: 15506045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.